208 related articles for article (PubMed ID: 35632722)
1. Depo Medroxyprogesterone (DMPA) Promotes Papillomavirus Infections but Does Not Accelerate Disease Progression in the Anogenital Tract of a Mouse Model.
Hu J; Brendle SA; Li JJ; Walter V; Cladel NM; Cooper T; Shearer DA; Balogh KK; Christensen ND
Viruses; 2022 May; 14(5):. PubMed ID: 35632722
[TBL] [Abstract][Full Text] [Related]
2. Plasma levels of medroxyprogesterone acetate (MPA), sex-hormone binding globulin, gonadal steroids, gonadotrophins and prolactin in women during long-term use of depo-MPA (Depo-Provera) as a contraceptive agent.
Jeppsson S; Gershagen S; Johansson ED; Rannevik G
Acta Endocrinol (Copenh); 1982 Mar; 99(3):339-43. PubMed ID: 6461995
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
Piya-Anant M; Koetsawang S; Patrasupapong N; Dinchuen P; d'Arcangues C; Piaggio G; Pinol A
Contraception; 1998 Jan; 57(1):23-8. PubMed ID: 9554247
[TBL] [Abstract][Full Text] [Related]
4. Influence of Hormonal Contraceptive Use and HIV on Cervicovaginal Cytokines and Microbiota in Malawi.
Haddad LB; Tang JH; Davis NL; Kourtis AP; Chinula L; Msika A; Tegha G; Hosseinipour MC; Nelson JAE; Hobbs MM; Gajer P; Ravel J; De Paris K
mSphere; 2023 Feb; 8(1):e0058522. PubMed ID: 36622252
[TBL] [Abstract][Full Text] [Related]
5. Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice.
Wessels JM; Nguyen PV; Vitali D; Mueller K; Vahedi F; Felker AM; Dupont HA; Bagri P; Verschoor CP; Deshiere A; Mazzulli T; Tremblay MJ; Ashkar AA; Kaushic C
Sci Rep; 2021 Feb; 11(1):3894. PubMed ID: 33594113
[TBL] [Abstract][Full Text] [Related]
6. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception.
Lei ZW; Wu SC; Garceau RJ; Jiang S; Yang QZ; Wang WL; Vander Meulen TC
Contraception; 1996 Jun; 53(6):357-61. PubMed ID: 8773423
[TBL] [Abstract][Full Text] [Related]
7. Bone density among long-term users of medroxyprogesterone acetate as a contraceptive.
Paiva LC; Pinto-Neto AM; Faundes A
Contraception; 1998 Dec; 58(6):351-5. PubMed ID: 10095971
[TBL] [Abstract][Full Text] [Related]
8. The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation.
Pardthaisong T; Yenchit C; Gray R
Contraception; 1992 Apr; 45(4):313-24. PubMed ID: 1387602
[TBL] [Abstract][Full Text] [Related]
9. [Contraception with injectable long-acting preparation depo-provera].
Prilepskaia VN; Kondrikov NI; Tagieva TT
Akush Ginekol (Mosk); 1995; (3):7-10. PubMed ID: 7653732
[TBL] [Abstract][Full Text] [Related]
10. Medroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection.
Quispe Calla NE; Vicetti Miguel RD; Boyaka PN; Hall-Stoodley L; Kaur B; Trout W; Pavelko SD; Cherpes TL
Mucosal Immunol; 2016 Nov; 9(6):1571-1583. PubMed ID: 27007679
[TBL] [Abstract][Full Text] [Related]
11. A randomized, single blind comparative trial of norethindrone enanthate and depo-medroxyprogesterone acetate in Bangladesh.
Swenson I; Khan AR; Jahan FA
Contraception; 1980 Mar; 21(3):207-15. PubMed ID: 6446442
[TBL] [Abstract][Full Text] [Related]
12. The contraceptive depot medroxyprogesterone acetate impairs mycobacterial control and inhibits cytokine secretion in mice infected with Mycobacterium tuberculosis.
Kleynhans L; Du Plessis N; Allie N; Jacobs M; Kidd M; van Helden PD; Walzl G; Ronacher K
Infect Immun; 2013 Apr; 81(4):1234-44. PubMed ID: 23381991
[TBL] [Abstract][Full Text] [Related]
13. Depo Provera. Position paper on clinical use, effectiveness and side effects.
Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
[TBL] [Abstract][Full Text] [Related]
14. The contraceptive use of depot medroxyprogesterone acetate.
Hickey M; Fraser I
Clin Obstet Gynecol; 1995 Dec; 38(4):849-58. PubMed ID: 8616981
[TBL] [Abstract][Full Text] [Related]
15. Norethisterone Enanthate Increases Mouse Susceptibility to Genital Infection with Herpes Simplex Virus Type 2 and HIV Type 1.
Quispe Calla NE; Vicetti Miguel RD; Torres AR; Trout W; Gabriel JM; Hatfield AM; Aceves KM; Kwiek JJ; Kaur B; Cherpes TL
Immunohorizons; 2020 Feb; 4(2):72-81. PubMed ID: 32047094
[TBL] [Abstract][Full Text] [Related]
16. Bone mineral density during long-term treatment with Norplant implants and depot medroxyprogesterone acetate. A cross-sectional study of Thai women.
Taneepanichskul S; Intaraprasert S; Theppisai U; Chaturachinda K
Contraception; 1997 Sep; 56(3):153-5. PubMed ID: 9347205
[TBL] [Abstract][Full Text] [Related]
17. Toxicology of depot medroxyprogesterone acetate.
Jordan A
Contraception; 1994 Mar; 49(3):189-201. PubMed ID: 8200213
[TBL] [Abstract][Full Text] [Related]
18. Some effects of depo-medroxyprogesterone acetate (DMPA): observations in the nursing infant and in the long-term user.
Dahlberg K
Int J Gynaecol Obstet; 1982 Feb; 20(1):43-8. PubMed ID: 6126406
[TBL] [Abstract][Full Text] [Related]
19. Progesterone increases susceptibility and decreases immune responses to genital herpes infection.
Kaushic C; Ashkar AA; Reid LA; Rosenthal KL
J Virol; 2003 Apr; 77(8):4558-65. PubMed ID: 12663762
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation.
Said S; Sadek W; Rocca M; Koetsawang S; Kirwat O; Piya-Anant M; Dusitsin N; Sethavanich S; Affandi B; Hadisaputra W; Kazi A; Ramos RM; d'Arcangues C; Belsey EM; Noonan E; Olayinka I; Pinol A
Hum Reprod; 1996 Oct; 11 Suppl 2():1-13. PubMed ID: 8982739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
